The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.
Jackson Peter Kim, MD
Advertisement
Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care
Articles by Jackson Peter Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5